Loading…
BioXcel Therapeutics, Inc. is projected to decline to $1.20 by 2027, a -8% move from its current price of $1.31. BTAI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.26 | $1.31 | $1.36 | -0.10% |
| May 30 | $1.23 | $1.31 | $1.39 | -0.20% |
| May 31 | $1.22 | $1.31 | $1.40 | -0.30% |
| Jun 1 | $1.20 | $1.30 | $1.42 | -0.40% |
| Jun 2 | $1.19 | $1.30 | $1.43 | -0.50% |
| Jun 3 | $1.18 | $1.30 | $1.44 | -0.60% |
| Jun 4 | $1.17 | $1.30 | $1.45 | -0.70% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.17 | $1.30 | $1.45 | -0.70% |
| Week 2 | $1.11 | $1.29 | $1.51 | -1.40% |
| Week 3 | $1.06 | $1.28 | $1.55 | -2.10% |
| Week 4 | $1.02 | $1.27 | $1.59 | -2.79% |
| Week 5 | $0.9894 | $1.26 | $1.62 | -3.47% |
| Week 6 | $0.9597 | $1.26 | $1.64 | -4.15% |
| Week 7 | $0.9327 | $1.25 | $1.67 | -4.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
IGALMI is a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
It also develops BXCL501, an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate BXCL701, an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.
The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics, Inc. (BTAI) is the asset BioXcel Therapeutics, Inc. as a public-facing biotechnology company focused on neuroscience and immuno-oncology through AI-enabled drug development. The current price is $1.31, and the company carries a market capitalization of $40.45M with a market rank of 4632.
Forecasts lay out a path from a neutral near term toward higher long-run prices, with a 2026 average price of $1.31 and a 2040 average of $1.71, rising further to a 2050 average of $3.81. The max estimates rise from $1.63 in 2026 to $8.42 in 2050, illustrating a broad upside potential over the forecast horizon.
In the nearer term, 2026 shows an average of $1.31 (neutral) with a 0% ROI, while 2027 and 2028 soften, showing average prices of $1.20 and $1.04 with negative ROIs. By 2030 the forecast pushes higher to an average of $1.43 with a 9.2% ROI and a neutral sentiment, and the path gradually improves into the 2040s, culminating in a bullish 2050 outlook with an average of $3.81 and a 191.1% ROI.
A major floor 27.5% below — a decisive break under it would weaken the trend.
The nearest floor, 20.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 44.3% above — clearing it would confirm fresh momentum.
Key BTAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BTAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.18 | Buy | $1.21 | Buy |
| MA 10 | $1.16 | Buy | $1.19 | Buy |
| MA 20 | $1.19 | Buy | $1.18 | Buy |
| MA 50 | $1.22 | Buy | $1.25 | Buy |
| MA 100 | $1.45 | Sell | $1.45 | Sell |
| MA 200 | $2.10 | Sell | $2.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.65 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 142.23 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.38 | Buy |
| Bollinger %B (20,2) | 0.93 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 67.38 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1.22 | Buy |
| ADX (14) | 13.17 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bullish sentiment overall.
RSI(14) is 60, suggesting room for movement without being overbought. The 50-day simple moving average sits at $1.22, currently below the 2.10 price level indicated by the 200-day simple moving average, which can imply earnings volatility over longer horizons.
The price has a defined near-term support at $1.04 and a near-term resistance at $1.31. Over the past 30 days, the price oscillated from a low of $0.9967 to a high of $1.72, and annualized volatility sits at 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.02 | $1.31 | $1.63 | 0% | Neutral | |
| $0.9034 | $1.20 | $1.71 | -8% | Neutral | |
| $0.7467 | $1.04 | $1.55 | -21% | Bearish | |
| $0.7394 | $1.06 | $1.66 | -19% | Bearish | |
| $0.961 | $1.43 | $2.31 | +9% | Neutral | |
| $0.9467 | $1.45 | $2.41 | +11% | Neutral | |
| $0.9223 | $1.46 | $2.48 | +11% | Neutral | |
| $0.9247 | $1.50 | $2.62 | +15% | Neutral | |
| $0.7822 | $1.31 | $2.32 | 0% | Neutral | |
| $0.8193 | $1.40 | $2.55 | +7% | Neutral | |
| $0.8824 | $1.71 | $3.36 | +30% | Bullish | |
| $1.72 | $3.81 | $8.42 | +191% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.02 | $1.31 | $1.55 | +0.00% |
| June 2026 | $1.08 | $1.28 | $1.57 | -2.39% |
| July 2026 | $0.9929 | $1.19 | $1.49 | -6.57% |
| August 2026 | $0.979 | $1.19 | $1.51 | -0.39% |
| September 2026 | $1.00 | $1.23 | $1.58 | +3.41% |
| October 2026 | $0.9761 | $1.21 | $1.57 | -2.01% |
| November 2026 | $0.95 | $1.18 | $1.55 | -2.01% |
| December 2026 | $0.9841 | $1.23 | $1.63 | +4.28% |
Click any year to see its month-by-month BTAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioXcel Therapeutics, Inc.'s 2026 outlook centres on $1.31, within a $1.02 to $1.63 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BTAI could reach as high as $1.71, with a base case around $1.20 and support toward $0.9034 — roughly -8% from $1.31. Price action looks broadly range-bound.
Expect BTAI to range from $0.7467 to $1.55 through 2028. The $1.04 average target implies a -21% move from current prices. That is -14% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
The BTAI price prediction for 2029 points to an average of $1.06 (low $0.7394, high $1.66) — a potential decline of -19% on today's $1.31. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, BTAI is projected to trade between $0.961 and $2.31, averaging $1.43 — a potential gain of +9% from today's $1.31. That is up +34% on the projected 2029 average. A consolidation phase looks the most probable path here.
BioXcel Therapeutics, Inc.'s 2031 outlook centres on $1.45, within a $0.9467 to $2.41 range. That is up +2% on the projected 2030 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2032, BTAI could reach as high as $2.48, with a base case around $1.46 and support toward $0.9223 — roughly +11% from $1.31. A consolidation phase looks the most probable path here.
Expect BTAI to range from $0.9247 to $2.62 through 2033. The $1.50 average target implies a +15% move from current prices. That is up +3% on the projected 2032 average. Price action looks broadly range-bound.
The BTAI price prediction for 2034 points to an average of $1.31 (low $0.7822, high $2.32) — a potential decline of 0% on today's $1.31. A consolidation phase looks the most probable path here.
In 2035, BTAI is projected to trade between $0.8193 and $2.55, averaging $1.40 — a potential gain of +7% from today's $1.31. That is up +7% on the projected 2034 average. Price action looks broadly range-bound.
BioXcel Therapeutics, Inc.'s 2040 outlook centres on $1.71, within a $0.8824 to $3.36 range. That is up +22% on the projected 2035 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BTAI could reach as high as $8.42, with a base case around $3.81 and support toward $1.72 — roughly +191% from $1.31. Momentum favours further upside here.
Investing $1,000 in BTAI today (≈ 763.358779 BTAI) could be worth
$2,911.21
+$1,911.21 (+191%) by 2050 · US Dollar
Based on the average projected BTAI price of $3.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BTAIwould be worth at today's price.
$1,000 invested in BTAI on May 27, 2025 (≈ 719.424468 BTAI) would be worth
$942.45
-$57.55 (-5.8%) today · 0.94× · US Dollar
Based on a BTAI entry price of $1.39 vs. today's $1.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.09 | $1,201.83 | +20.2% |
| 1 month ago | $1.09 | $1,201.83 | +20.2% |
| 3 months ago | $1.76 | $744.32 | -25.6% |
| 6 months ago | $2.25 | $582.22 | -41.8% |
| 1 year ago | $1.39 | $942.45 | -5.8% |
| All time (5.0y) ago | $548.8 | $2.39 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BTAI forecast.
Our base-case forecast reaches $2.60 around 2050.
Implied market cap at $2.60: $80.28M
The multi-year forecast shows a mixed near-term path but a clear long-horizon expansion. In 2026 the average is $1.31 with a 0% ROI and a neutral sentiment. The sequence through 2029 remains broadly neutral to bearish, with 2027 at $1.20 (−8.4% ROI), 2028 at $1.04 (−20.9%), and 2029 at $1.06 (−18.8%).
From 2030 onward, the average price climbs to $1.43 with 9.2% ROI and remains neutral, then slowly edges higher to $1.45 (10.9%) in 2031 and $1.46 (11.3%) in 2032, with 2033 at $1.50 (14.7%). The 2034 forecast is $1.31 (−0.3%), and 2035 is $1.40 (7.2%). The outlook strengthens into the 2040s, with 2040 averaging $1.71 and a 30.3% ROI, and the long-run 2050 projection rising to an average of $3.81 with a 191.1% ROI.
These figures are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
Avg $1.43 in 2030, with a min of $0.961, max of $2.31 and an ROI of 9.2%.
The forecast shows positive ROIs in 2030 (9.2%), 2040 (30.3%), and 2050 (191.1%), but near-term years 2027 (−8.4%), 2028 (−20.9%), and 2029 (−18.8%) are negative, with 2026 at 0% ROI.
Yes. The forecast maximums include $2.31 in 2030, $2.41 in 2031, $2.48 in 2032, and $2.62 in 2033.
Current price is $1.31 and market cap is $40.45M.
Sentiment is BULLISH; RSI(14) is 60; SMA50 is $1.22; SMA200 is $2.10; support is $1.04 and resistance is $1.31; 30-day range is $0.9967 to $1.72; annualized volatility is 80%.
BioXcel Therapeutics, Inc. Community Discussion
0Share your BioXcel Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.